Cargando…
Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy
Although multiple sclerosis (MS) and multiple system atrophy (MSA) are both characterized by impaired oligodendrocytes (OLs), the aetiological relevance remains obscure. Given inherent stressors affecting OLs, the objective of the present study was to discuss the possible role of amyloidogenic evolv...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928476/ https://www.ncbi.nlm.nih.gov/pubmed/36785484 http://dx.doi.org/10.1080/19336896.2023.2172912 |
_version_ | 1784888658319376384 |
---|---|
author | Wei, Jianshe Ho, Gilbert Masliah, Eliezer Hashimoto, Makoto |
author_facet | Wei, Jianshe Ho, Gilbert Masliah, Eliezer Hashimoto, Makoto |
author_sort | Wei, Jianshe |
collection | PubMed |
description | Although multiple sclerosis (MS) and multiple system atrophy (MSA) are both characterized by impaired oligodendrocytes (OLs), the aetiological relevance remains obscure. Given inherent stressors affecting OLs, the objective of the present study was to discuss the possible role of amyloidogenic evolvability (aEVO) in these conditions. Hypothetically, in aEVO, protofibrils of amyloidogenic proteins (APs), including β-synuclein and β-amyloid, might form in response to diverse stressors in parental brain. Subsequently, the AP protofibrils might be transmitted to offspring via germ cells in a prion-like fashion. By virtue of the stress information conferred by protofibrillar APs, the OLs in offspring’s brain might be more resilient to forthcoming stressors, perhaps reducing MS risk. aEVO could be comparable to a gene for the inheritance of acquired characteristics. On the contrary, during ageing, MSA risk is increased through antagonistic pleiotropy. Consistently, the expression levels of APs are reduced in MS, but are increased in MSA compared to controls. Furthermore, β-synuclein, the non-amyloidogenic homologue of β-synuclein, might exert a buffering effect on aEVO, and abnormal β-synuclein could also increase MS and MSA disease activity. Collectively, a better understanding of the role of aEVO in the OL diseases might lead to novel interventions for such chronic degenerative conditions. |
format | Online Article Text |
id | pubmed-9928476 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-99284762023-02-15 Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy Wei, Jianshe Ho, Gilbert Masliah, Eliezer Hashimoto, Makoto Prion Commentaries and Views Although multiple sclerosis (MS) and multiple system atrophy (MSA) are both characterized by impaired oligodendrocytes (OLs), the aetiological relevance remains obscure. Given inherent stressors affecting OLs, the objective of the present study was to discuss the possible role of amyloidogenic evolvability (aEVO) in these conditions. Hypothetically, in aEVO, protofibrils of amyloidogenic proteins (APs), including β-synuclein and β-amyloid, might form in response to diverse stressors in parental brain. Subsequently, the AP protofibrils might be transmitted to offspring via germ cells in a prion-like fashion. By virtue of the stress information conferred by protofibrillar APs, the OLs in offspring’s brain might be more resilient to forthcoming stressors, perhaps reducing MS risk. aEVO could be comparable to a gene for the inheritance of acquired characteristics. On the contrary, during ageing, MSA risk is increased through antagonistic pleiotropy. Consistently, the expression levels of APs are reduced in MS, but are increased in MSA compared to controls. Furthermore, β-synuclein, the non-amyloidogenic homologue of β-synuclein, might exert a buffering effect on aEVO, and abnormal β-synuclein could also increase MS and MSA disease activity. Collectively, a better understanding of the role of aEVO in the OL diseases might lead to novel interventions for such chronic degenerative conditions. Taylor & Francis 2023-02-13 /pmc/articles/PMC9928476/ /pubmed/36785484 http://dx.doi.org/10.1080/19336896.2023.2172912 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentaries and Views Wei, Jianshe Ho, Gilbert Masliah, Eliezer Hashimoto, Makoto Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy |
title | Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy |
title_full | Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy |
title_fullStr | Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy |
title_full_unstemmed | Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy |
title_short | Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy |
title_sort | differential involvement of amyloidogenic evolvability in oligodendropathies; multiple sclerosis and multiple system atrophy |
topic | Commentaries and Views |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928476/ https://www.ncbi.nlm.nih.gov/pubmed/36785484 http://dx.doi.org/10.1080/19336896.2023.2172912 |
work_keys_str_mv | AT weijianshe differentialinvolvementofamyloidogenicevolvabilityinoligodendropathiesmultiplesclerosisandmultiplesystematrophy AT hogilbert differentialinvolvementofamyloidogenicevolvabilityinoligodendropathiesmultiplesclerosisandmultiplesystematrophy AT masliaheliezer differentialinvolvementofamyloidogenicevolvabilityinoligodendropathiesmultiplesclerosisandmultiplesystematrophy AT hashimotomakoto differentialinvolvementofamyloidogenicevolvabilityinoligodendropathiesmultiplesclerosisandmultiplesystematrophy |